Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel. METHODS: In this multicenter, double-blind, randomized trial, we compared ticagrelor (180-mg loading dose, 90 mg twice daily thereafter) and clopidogrel (300-to-600-mg loading dose, 75 mg daily thereafter) for the prevention of cardiovascular events in 18,624 patients admitted to the hospital with an acute coronary syndrome, with or without ST-segment elevation. RESULTS: At 12 months, the primary end point--a composite of death from vascular causes, myocardial infarction, or stroke--had occurred in 9.8% of patients receiving ticagrelor as compared with 11.7% of those receiving clopidogrel (hazard ratio, 0.84; 95% confidence interval [CI], 0.77 to 0.92; P<0.001). Predefined hierarchical testing of secondary end points showed significant differences in the rates of other composite end points, as well as myocardial infarction alone (5.8% in the ticagrelor group vs. 6.9% in the clopidogrel group, P=0.005) and death from vascular causes (4.0% vs. 5.1%, P=0.001) but not stroke alone (1.5% vs. 1.3%, P=0.22). The rate of death from any cause was also reduced with ticagrelor (4.5%, vs. 5.9% with clopidogrel; P<0.001). No significant difference in the rates of major bleeding was found between the ticagrelor and clopidogrel groups (11.6% and 11.2%, respectively; P=0.43), but ticagrelor was associated with a higher rate of major bleeding not related to coronary-artery bypass grafting (4.5% vs. 3.8%, P=0.03), including more instances of fatal intracranial bleeding and fewer of fatal bleeding of other types. CONCLUSIONS: In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rate of overall major bleeding but with an increase in the rate of non-procedure-related bleeding. (ClinicalTrials.gov number, NCT00391872.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In patients with ACS undergoing PCI, 12 months' DAPT with low-dose ASA and prasugrel or ticagrelor was superior to DAPT with clopidogrel in the diabetes sub-group of the respective RCTs, with a benefit-risk profile similar to the overall trial populations (Supplementary data online, Tables S12-13).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [311]
In the citing paper
“In patients with ACS for whom an early invasive strategy is planned, dual antiplatelet therapy with a P2Y12 inhibitor (ticagrelor or prasugrel) added to aspirin was superior to clopidogrel and aspirin.”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [503]
In the citing paper
“With ticagrelor given for 12 months the composite endpoint of death from vascular causes, myocardial infarction, or stroke occurred in 9.8% as compared with 11.7% of those receiving clopidogrel (HR 0.84, 95% CI 0.77-0.92;P , 0.001).No significant difference in rate of major bleeding was found.501 -503”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [503]
In the citing paper
“International trials of various pharmacotherapies have sometimes found discordant results in patients enrolled in the United States than seen in overall trial results.19–32”
From REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States (2020) · cites this paper as [19]
In the citing paper
“The reasons range from low numbers of patients enrolled in the United States to potential differences in background medical management or in patient risk profiles.”
From REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States (2020) · cites this paper as [19]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Writing Committee Members, Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134791.68010.fa · Cited by 8,356
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Self-citationBraunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D., Kupersmith, J., Levin, T. N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.10.1193 · Cited by 4,487
Universal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., White, H. D., TASK FORCE MEMBERS: Chairpersons: Kristian Thygesen (Denmark), J. S. A. (., Biomarker Group: Allan S. Jaffe, C. (., ECG Group: Bernard Chaitman, C.-O. (., Imaging Group: Richard Underwood, C. (., Intervention Group: Jean-Pierre Bassand, C.-O. (., Clinical Investigation Group: Paul W. Armstrong, C. (., Global Perspective Group: Philip A. Poole-Wilson, C. (., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.187397 · Cited by 4,230
Mehta, S. R., Yusuf, S., Peters, R. J., Bertrand, M. E., Lewis, B. S., Natarajan, M. K., Malmberg, K., Rupprecht, H.-J., Zhao, F., Chrolavicius, S., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05701-4 · Cited by 2,809
急性心筋梗塞の疑いのある17187症例におけるストレプトキナーゼ静脈内投与,アスピリン経口投与,上記2つの併用または無処置の無作偽試験 ISIS-2
Dienstl, F., Backer, G. D., Cairns, J., Pedersen, F., Kala, R., Boissel, J., Schroeder, R., Horgan, J., & Tognoni, G. (1988) · The Lancet · Cited by 2,754
Mehta, S. R., Yusuf, S., & Peters, R. J. G. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00559-7 · Cited by 2,578
Research works printed but not linked: 2
- 10.1016/S0140-6736(01)05701-4 · DOI · Paper page
- 1988, Lancet, 2, 349
Cited by
Items 801–900 of 1,005
Moore, K. T., Plotnikov, A. N., Thyssen, A., Vaccaro, N. M., Ariyawansa, J., & Burton, P. B. J. (2011) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31822f6c2b · Cited by 59
Banerjee, S., Weideman, R. A., Weideman, M. W., Little, B. B., Kelly, K. C., Gunter, J. T., Tortorice, K. L., Shank, M., Cryer, B., Reilly, R. F., et al. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.10.073 · Cited by 59
Mangiacapra, F., Müller, O., Ntalianis, A., Trana, C., Heyndrickx, G. R., Bartúnek, J., Vanderheyden, M., Wijns, W. C., Bruyne, B. D., & Barbato, E. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.06.044 · Cited by 59
Rollini, F., Franchi, F., Cho, J. R., DeGroat, C., Bhatti, M., Muñiz‐Lozano, A., Singh, K., Ferrante, E., Wilson, R. E., Dunn, E. C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv744 · Cited by 63
Tang, X., Li, R., Jing, Q., Wang, Q., Liu, P., Zhang, P., & Liu, Y. (2016) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000390 · Cited by 59
Melloni, C., Cornel, J. H., Hafley, G. E., Neely, M. L., Clemmensen, P. M., Zamoryakhin, D., Prabhakaran, D., White, H. D., Fox, K. A. A., Ohman, E. M., et al. (2015) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872615598631 · Cited by 63
Reperfusion strategies in acute myocardial infarction and multivessel disease
Vogel, B., Mehta, S. R., & Mehran, R. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.88 · Cited by 60
Gargiulo, G., Valgimigli, M., Capodanno, D., & Bittl, J. A. (2017) · EuroIntervention · doi:10.4244/eij-d-17-00468 · Cited by 63
Cornel, J. H., Becker, R. C., Goodman, S. G., Husted, S., Katus, H. A., Santoso, A., Steg, P. G., Storey, R. F., VINTILA, M. M., Sun, J. L., et al. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.06.005 · Cited by 58
Self-citationAbraham, N. S., Noseworthy, P. A., Inselman, J., Herrin, J. S., Yao, X., Sangaralingham, L. R., Cornish, G., Ngufor, C. G., & Shah, N. D. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.05.017 · Cited by 69
Drugs targeting adenosine signaling pathways: A current view
Kutryb-Zając, B. A., Kawecka, A., Nasadiuk, K., Braczko, A., Stawarska, K., Caiazzo, E., Koszałka, P., & Cicala, C. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115184 · Cited by 64
Ndounga Diakou, L. A., Trinquart, L., Hróbjartsson, A., Barnes, C., Yavchitz, A., Ravaud, P., & Boutron, I. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000043.pub2 · Cited by 58
Nakamura, M., Isshiki, T., Kimura, T., Ogawa, H., Yokoi, H., Nanto, S., Takayama, M., Kitagawa, K., Ikeda, Y., & Saito, S. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.01.026 · Cited by 59
Saw, J., Wong, G. C., Mayo, J. R., Bernstein, V., Mancini, G. B. J., Ye, J., Skarsgard, P. L., Starovoytov, A., & Cairns, J. A. (2016) · Heart · doi:10.1136/heartjnl-2015-308691 · Cited by 62
Vaduganathan, M., Harrington, R. A., Stone, G. W., Deliargyris, E., Steg, P. G., Gibson, C. M., Hamm, C. W., Price, M. J., Menozzi, A., Prats, J., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.10.055 · Cited by 58
Self-citationChiarito, M., Cao, D., Cannata, F., Godino, C., Lodigiani, C., Ferrante, G., Lópes, R. D., Alexander, J. H., Reimers, B., Condorelli, G., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2017.5306 · Cited by 64
Novel aspects of antiplatelet therapy in cardiovascular disease
Gremmel, T., Michelson, A. D., Frelinger, A. L., & Bhatt, D. L. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12115 · Cited by 61
van Leeuwen, M. A. H., van der Hoeven, N. W., Janssens, G. N., Everaars, H., Nap, A., Lemkes, J. S., de Waard, G. A., van de Ven, P. M., van Rossum, A. C., ten Cate, T. J. F., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.035931 · Cited by 61
Kotecha, T., & Rakhit, R. D. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-6-s43 · Cited by 72
Clemmensen, P. M., Grieco, N. B., İnce, H., Danchin, N., Gödicke, J., Ramos, Y., Schmitt, J., Goldstein, P., & on behalf of the MULTIPRAC study investigators (2014) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872614547449 · Cited by 58
Martin, A., Berndt, C., Calmette, L., Philip, I., Decouture, B., Gaussem, P., Gouin‐Thibault, I., Samama, C. M., Bachelot‐Loza, C., & Godiér, A. (2015) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000000348 · Cited by 57
Capodanno, D., & Angiolillo, D. J. (2020) · Circulation · doi:10.1161/circulationaha.120.045465 · Cited by 65
Park, K. Y., Ozaki, T., Kostynskyy, A., Kortman, H. G. J., Hilário, A. F. L., Nicholson, P. J., Agid, R., Krings, T., & Pereira, V. M. (2021) · American Journal of Neuroradiology · doi:10.3174/ajnr.a7216 · Cited by 57
“9%).(13) Narata et al(34) also reported 1 case of dyspnea.”
BackgroundInfluentialOzaki, Y., Tobe, A., Onuma, Y., Kobayashi, Y., Amano, T., Muramatsu, T., Ishii, H., Yamaji, K., Kohsaka, S., Ismail, T. F., et al. (2024) · Cardiovascular Intervention and Therapeutics · doi:10.1007/s12928-024-01036-y · Cited by 69
“These real-world outcomes are consistent with the results of the landmark Platelet Inhibition and Patient Outcomes (PLATO) trial [55].”
ResultPerioperatives Management von Patienten mit Koronarstents bei nichtherzchirurgischen Eingriffen
Jámbor, C., Spannagl, M., & Zwißler, B. (2009) · Der Anaesthesist · doi:10.1007/s00101-009-1628-7 · Cited by 58
Nylander, S., Wågberg, F., Andersson, M., Skärby, T., & Gustafsson, D. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13027 · Cited by 57
Implications of geographical variation on clinical outcomes of cardiovascular trials
Mentz, R. J., Kaski, J. C., Dan, G., Goldstein, S., Stockbridge, N., Alonso-García, Á., Ruilope, L. M., Martínez, F. A., Zannad, F. M., Pitt, B., et al. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.06.006 · Cited by 54
Sillén, H., Cook, M., & Davis, P. C. (2011) · Journal of Chromatography B · doi:10.1016/j.jchromb.2011.06.023 · Cited by 57
Mewhort, H. E., Turnbull, J. D., Satriano, A., Chow, K., Flewitt, J. A., Andrei, A., Guzzardi, D. G., Svystonyuk, D. A., White, J. A., & Fedak, P. W. M. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2016.01.012 · Cited by 70
Bertoluci, M. C., Moreira, R. O., Faludi, A. Á., Izar, M. C. D. O., Schaan, B. D., Valério, C. M., Bertolami, M. C., Chacra, A. P. M., Malachias, M. V. B., Vencio, S. A. C., et al. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0251-z · Cited by 69
“03), including more instances of fatal intracranial bleeding and fewer of fatal bleeding of other types [165].”
BackgroundZocca, P., van der Heijden, L. C., Kok, M. M., Löwik, M. M., Hartmann, M., Stoel, M. G., Louwerenburg, J. H., de Man, F. H. A. F., Linssen, G. C. M., Knottnerus, I. L. H., et al. (2017) · EuroIntervention · doi:10.4244/eij-d-17-00634 · Cited by 66
Tuteja, S., Glick, H. A., Matthai, W., Nachamkin, I., Nathan, A. S., Monono, K., Carcuffe, C., Maslowski, K., Chang, G., Kobayashi, T., et al. (2020) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.119.002640 · Cited by 66
Casieri, V., Matteucci, M., Pasanisi, E. M., Papa, A., Barile, L., Fritsche‐Danielson, R., & Lionetti, V. (2020) · Scientific Reports · doi:10.1038/s41598-020-59225-7 · Cited by 59
Regulators of Platelet cAMP Levels: Clinical and Therapeutic Implications
Noe, L., Peeters, K., Izzi, B., Geet, C. V., & Freson, K. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710792065018 · Cited by 67
Newer agents in antiplatelet therapy: a review
Holinstat, M. A., & Yeung, J. (2012) · Journal of Blood Medicine · doi:10.2147/jbm.s25421 · Cited by 73
Menichelli, M., Neumann, F., Ndrepepa, G., Mayer, K., Wöhrle, J., Bernlochner, I., Richardt, G., Witzenbichler, B., Sibbing, D., Gewalt, S., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m20-1806 · Cited by 58
“In addition, whereas bare-metal stents and first-generation drug-eluting stents were the most frequently used devices in previous trials on prasugrel (5) and ticagrelor (9), with more than 90% of the patients receiving new-generation drug-eluting stents in the present study, it reflects much better contemporary PCI st…”
BackgroundHögberg, C., Gidlöf, O., Tan, C., Svensson, S., Nilsson‐Öhman, J., Erlinge, D., & Olde, B. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.04158.x · Cited by 56
Wang, X., Dai-fu, Z., Zhuang, S., & Lai, Y. (2011) · Clinical Cardiology · doi:10.1002/clc.20884 · Cited by 56
Crespin, D., Federspiel, J. J., Biddle, A. K., Jonas, D. E., & Rossi, J. S. (2011) · Value in Health · doi:10.1016/j.jval.2010.11.012 · Cited by 57
Platelet Function Profiles in Patients with Diabetes Mellitus
Rollini, F., Franchi, F., Muñiz‐Lozano, A., & Angiolillo, D. J. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-013-9449-0 · Cited by 61
Trenk, D., Schrör, K., Gawaz, M., Kristensen, S. D., Storey, R. F., Huber, K., Siller-Matula, J. M., & for the European Platelet Academy (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-03-0238 · Cited by 63
Self-citationNikolsky, E., Mehran, R., Dangas, G., Yu, J., Parise, H., Xu, K., Pocock, S., & Stone, G. W. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.10.046 · Cited by 58
Vora, A. N., Wang, T. Y., Hellkamp, A. S., Thomas, L. E., Henry, T. D., Goyal, A., & Roe, M. T. (2016) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.115.002312 · Cited by 56
Li, Y., Wang, Y.-C., Wang, Y., Liu, J., Lee, C., Chen, C., Hsieh, C., Kuo, F. Y., Huang, W., Sung, S., et al. (2018) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.06.002 · Cited by 59
Soize, S., Foussier, C., Manceau, P.-F., Litré, C., Backchine, S., Gawlitza, M., & Pierot, L. (2019) · Journal of Neuroradiology · doi:10.1016/j.neurad.2019.01.094 · Cited by 56
Martin, J., Williams, A. K., Klein, M. D., Sriramoju, V., Madan, S., Rossi, J. S., Clarke, M. M., Cicci, J. D., Cavallari, L. H., Weck, K. E., et al. (2019) · Genetics in Medicine · doi:10.1038/s41436-019-0611-1 · Cited by 59
microRNAs as Promising Biomarkers of Platelet Activity in Antiplatelet Therapy Monitoring
Krammer, T. L., Mayr, M., & Hackl, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103477 · Cited by 59
Danchin, N., Lettino, M., Zeymer, U., Widimský, P., Bardajı́, A., Barrabés, J. A., Cequier, A. R., Claeys, M. J., Luca, L. D., Dörler, J., et al. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw003 · Cited by 55
ST elevation myocardial infarction
Choudhury, T. R., West, N. E. J., & El‐Omar, M. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-3-277 · Cited by 71
Update on Antithrombotic Therapy after Percutaneous Coronary Intervention
Saito, Y., & Kobayashi, Y. (2019) · Internal Medicine · doi:10.2169/internalmedicine.3685-19 · Cited by 57
Ticagrelor or Prasugrel in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes
Valina, C. M., Neumann, F., Menichelli, M., Mayer, K., Wöhrle, J., Bernlochner, I., Aytekin, A., Richardt, G., Witzenbichler, B., Sibbing, D., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.09.584 · Cited by 63
Meune, C., Zuily, S., Wahbi, K., Claessens, Y.-É., Weber, S., & Chenevier‐Gobeaux, C. (2010) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2010.11.002 · Cited by 58
Contemporary use of glycoprotein IIb/IIIa inhibitors
Würtz, M., Grove, E. L., Caterina, R., Huber, K., Moliterno, D. J., Neumann, F., & Kristensen, S. D. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-07-0468 · Cited by 59
Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor
Giorgi, M. A., Arazi, H. C., González, C. D., & Girolamo, G. D. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.550573 · Cited by 56
Serruys, P. W. J. C., Garg, S., Abizaid, A., Ormiston, J., Windecker, S., Verheye, S., Dubois, C., Stewart, J. T., Hauptmann, K. E., Schöfer, J., et al. (2010) · EuroIntervention · doi:10.4244/eijv6i2a32 · Cited by 55
Urban, P. M., Abizaid, A., BANNING, A. P., Bartorelli, A. L., Baux, A. C., Džavík, V., Ellis, S. G., Gao, R., Holmes, D. R., Jeong, M. H., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.028 · Cited by 54
Campo, G. C., Sega, F. V. D., Pavasini, R., Aquila, G., Gallo, F., Fortini, F., Tonet, E., Cimaglia, P., Franco, A. D., Pestelli, G., et al. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-12-0973 · Cited by 55
Therapeutic strategies for atherosclerosis and atherothrombosis: Past, present and future
Weber, C., Badimón, L., Mach, F., & van der Vorst, E. P. C. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-10-0814 · Cited by 60
“The PLATO trial confirmed superiority of ticagrelor regarding major cardiovascular events, although an increased bleeding risk in non-bypass surgery was observed (51).”
MethodFaludi, A., Izar, M., Saraiva, J., Bianco, H. T., Chacra, A., Bertoluci, M., Moreira, R., Turatti, L., Bertolami, A., Sulzbach, M. L., et al. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20170188 · Cited by 107
Mahla, E., Tantry, U. S., Prüller, F., & Gurbel, P. A. (2018) · Circulation · doi:10.1161/circulationaha.118.035160 · Cited by 58
Varenhorst, C., Jensevik, K., Jernberg, T., Sundstrom, A., Hasvold, P., Held, C., Lagerqvist, B., & James, S. K. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht438 · Cited by 61
Self-citationAntithrombotic Management of Elderly Patients With Coronary Artery Disease
Capranzano, P., & Angiolillo, D. J. (2021) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2021.01.040 · Cited by 60
The State of Periprocedural Antiplatelet Therapy After Recent Trials
Desai, N. R., & Bhatt, D. L. (2010) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2010.04.008 · Cited by 54
Nawarskas, J. J., & Clark, S. M. (2011) · Cardiology in Review · doi:10.1097/crd.0b013e3182099d86 · Cited by 57
Bell, A., Roussin, A., Cartier, R., Chan, W., Douketis, J. D., Gupta, A. K., Kraw, M. E., Lindsay, T. F., Love, M. P., Pannu, N., et al. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2010.12.033 · Cited by 74
Changes in Inflammatory Biomarkers in Patients Treated With Ticagrelor or Clopidogrel
Husted, S., Storey, R. F., Harrington, R. A., Emanuelsson, H., & Cannon, C. P. (2010) · Clinical Cardiology · doi:10.1002/clc.20732 · Cited by 57
Self-citationMahaffey, K. W., Held, C., WOJDYLA, D. M., James, S. K., Katus, H. A., Husted, S., Steg, P. G., Cannon, C. P., Becker, R. C., Storey, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.038 · Cited by 54
Self-citationAndersson, C., Lyngbæk, S., Nguyen, C. D., Nielsen, M. R. I., Gislason, G., Køber, L., & Torp-Pedersen, C. T. (2012) · JAMA · doi:10.1001/2012.jama.10779 · Cited by 55
Rakowski, T., Dudek, D., Dziewierz, A., Yu, J., Witzenbichler, B., Guagliumi, G., Kornowski, R., Hartmann, F. S., Lansky, A. J., Brener, S. J., et al. (2013) · EuroIntervention · doi:10.4244/eijv8i11a199 · Cited by 54
New antithrombotic agents—insights from clinical trials
Paikin, J. S., Eikelboom, J. W., Cairns, J. A., & Hirsh, J. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.101 · Cited by 58
Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice
Muñiz‐Lozano, A., Rollini, F., Franchi, F., & Angiolillo, D. J. (2013) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944713487781 · Cited by 58
Bangalore, S., Singh, A., Toklu, B., DiNicolantonio, J. J., Croce, K., Feit, F., & Bhatt, D. L. (2014) · Open Heart · doi:10.1136/openhrt-2014-000068 · Cited by 55
Antiplatelet therapy at the time of coronary artery bypass grafting: a multicentre cohort study
Kremke, M., Tang, M., Bak, M., Kristensen, K. L., Hindsholm, K., Andreasen, J. J., Hjortdal, V. E., & Jakobsen, C.-J. (2013) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezt230 · Cited by 54
Ticagrelor and Rosuvastatin Have Additive Cardioprotective Effects via Adenosine
Birnbaum, Y., Birnbaum, G. D., Birnbaum, I., Nylander, S., & Ye, Y. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6701-2 · Cited by 53
O’Fee, K., Deych, E., Ciani, O., & Brown, D. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.5726 · Cited by 59
FILIPPO, O. D., D’Ascenzo, F., Raposeiras‐Roubín, S., Abu‐Assi, E., Peyracchia, M., Bocchino, P. P., Kinnaird, T. D., Ariza‐Solé, A., Liebetrau, C., Manzano‐Fernández, S., et al. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz048 · Cited by 53
Vranckx, P., Valgimigli, M., Odutayo, A., Serruys, P. W. J. C., Hamm, C. W., Steg, P. G., Heg, D., Fadden, E. P. M., Onuma, Y., Benit, E., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.119.015560 · Cited by 55
“4 However, ticagrelor has not been tested in the setting of elective PCI for SCAD.”
Self-citationPersonalised antiplatelet therapies for coronary artery disease: what the future holds
Capodanno, D., & Angiolillo, D. J. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad362 · Cited by 58
Gremmel, T., Frelinger, A. L., & Michelson, A. D. (2024) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0044-1786387 · Cited by 65
“223 – 225 In contrast, no antagonists of the P2Y 1 receptor have been approved for clinical use.”
Platelet reactivity during ticagrelor maintenance therapy: A patient-level data meta-analysis
Alexopoulos, D. K., Xanthopoulou, I., Storey, R. F., Bliden, K. P., Tantry, U. S., Angiolillo, D. J., & Gurbel, P. A. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.06.026 · Cited by 58
Self-citationBecker, R. C., Scheiman, J. M., Dauerman, H. L., Spencer, F. A., Rao, S. V., Sabatine, M. S., Johnson, D. A., Chan, F., Abraham, N. S., & Quigley, E. M. M. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.09.012 · Cited by 53
Self-citationDiretrizes Brasileiras de Antiagregantes Plaquetários e Anticoagulantes em Cardiologia
Filho, A. M. L., Azmus, A., Soeiro, A., Quadros, A., Avezum, Á., Marques, A., Franci, A., Manica, A., Volschan, A., de Paola, A., et al. (2013) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.2013s009 · Cited by 95
Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis
Cornelissen, I., Palmer, D., David, T., Wilsbacher, L. D., Concengco, C., Conley, P. B., Pandey, A., & Coughlin, S. R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013309107 · Cited by 53
Antiplatelet drug interactions with proton pump inhibitors
Scott, S. A., Obeng, A. O., & Hulot, J. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.856883 · Cited by 61
Grześk, G., Koziński, M., Navarese, E. P., Krzyżanowski, M., Grześk, E., Kubica, A., Siller-Matula, J. M., Castriota, F., & Kubica, J. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2011.12.029 · Cited by 55
Vessel wall, not platelet, P2Y12 potentiates early atherogenesis
West, L. E., Steiner, T., Judge, H. M., Francis, S., & Storey, R. F. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu028 · Cited by 59
Self-citationCurrent therapies and investigational drugs for peripheral arterial disease
Suzuki, J.-I., Shimamura, M., Suda, H., Wakayama, K., Kumagai, H., Ikeda, Y., Akazawa, H., Isobe, M., Komuro, I., & Morishita, R. (2015) · Hypertension Research · doi:10.1038/hr.2015.134 · Cited by 56
Aradi, D., Groß, L., Trenk, D., Geisler, T., Merkely, B. P., Kiss, R. G., Komócsi, A., Dézsi, C. A., Ruzsa, Z., Ungi, I., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz202 · Cited by 60
Karathanos, A., Lin, Y., Dannenberg, L., Parco, C., Schulze, V., Brockmeyer, M., Jung, C., Heinen, Y., Perings, S. M., Zeymer, U., et al. (2019) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.05.003 · Cited by 55
Stroke in Patients With Peripheral Artery Disease
Kolls, B. J., Sapp, S. K., Rockhold, F. W., Jordan, J. D., Dombrowski, K. E., Fowkes, F. G. R., Mahaffey, K. W., Berger, J. S., Katona, B. G., Blomster, J., et al. (2019) · Stroke · doi:10.1161/strokeaha.118.023534 · Cited by 55
Self-citationPodlasek, A., Sultan, A. S. A., Assis, Z., Kashani, N., Goyal, M., & Almekhlafi, M. (2019) · Journal of NeuroInterventional Surgery · doi:10.1136/neurintsurg-2019-014996 · Cited by 53
Acute management of unstable angina and non-ST segment elevation myocardial infarction
Morita, F., Pesaro, A. E. P., Franken, M., & Wajngarten, M. (2015) · Einstein (São Paulo) · doi:10.1590/s1679-45082015rw3172 · Cited by 59
Rosselló, X., Bueno, H., Pocock, S., de Werf, F. V., Danchin, N., Annemans, L., Medina, J., & Zeymer, U. (2018) · Clinical Cardiology · doi:10.1002/clc.23116 · Cited by 55
“Data from randomized clinical trials show substantially lower mortality rates in the first year after the index MI.(19,20) For example, in the Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of AspirinThrombolysis in Myocardial Infarction 54…”
MethodInfluentialNguyen, A. B., Cavallari, L. H., Rossi, J. S., Stouffer, G. A., & Lee, C. R. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.991646 · Cited by 54
“Outcomes by Optimizing Platelet Inhibition with Prasugrel– Thrombolysis in Myocardial Infarction (TRITON–TIMI) 38 and Study of Platelet Inhibition and Patient Outcomes (PLATO) randomized clinical trials, prasugrel and ticagrelor displayed superior efficacy compared to clopidogrel in acute coronary syndrome (ACS) patie…”
BackgroundMethodWarner, T. D., Armstrong, P. C. J., Curzen, N. P., & Mitchell, J. A. (2010) · Heart · doi:10.1136/hrt.2010.205724 · Cited by 57
Sharma, R., Reddy, Singh, V. N., Sharma, Voelker, & Bhatt, D. L. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s6787 · Cited by 48
Johansson, Å., Eriksson, N., Lindholm, D. P., Varenhorst, C., James, S. K., Syvänen, A., Axelsson, T., Siegbahn, A., Barratt, B. J., Becker, R. C., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw012 · Cited by 59
Self-citationCaroff, E., Hubler, F., Meyer, E. A., Renneberg, D., Gnerre, C., Treiber, A., Rey, M., Hess, P., Steiner, B., Hilpert, K., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00933 · Cited by 52
Adelborg, K., Grove, E. L., Sundbøll, J., Laursen, M., & Schmidt, M. (2016) · Heart · doi:10.1136/heartjnl-2016-309402 · Cited by 57
Cheyne–Stokes Respiration, Chemoreflex, and Ticagrelor-Related Dyspnea
Giannoni, A., Emdin, M., & Passino, C. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1601662 · Cited by 52
Metadata
- Authors
- Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., Mahaffey, K. W., Scirica, B. M., Skene, A., Steg, P. G., Storey, R. F., & Harrington, R. A.
- Affiliations
- Uppsala University (SE)
- Duke Clinical Research Institute (US)
- Grochowski Hospital (PL)
- Brigham and Women's Hospital (US)
- AstraZeneca (Sweden) (SE)
- Aarhus University Hospital (DK)
- University Hospital Heidelberg (DE)
- University of Sheffield (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-09-10
- Volume
- 361
- Issue
- 11
- Pages
- 1045-1057
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140501627
- Cited by
- 7,117
- References
- 35
- Citations by year
- 2026: 214 · 2025: 277 · 2024: 267 · 2023: 359 · 2022: 411 · 2021: 454 · 2020: 500 · 2019: 472 · 2018: 473 · 2017: 480 · 2016: 494 · 2015: 522 · 2014: 467 · 2013: 520 · 2012: 464
- FWCI
- 253.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Open Repository and Bibliography (University of Liège) (submittedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- ticagrelor, clopidogrel, acute coronary syndrome, ST-elevation myocardial infarction, P2Y12 inhibitors, platelet aggregation inhibition, major adverse cardiovascular events, major bleeding, intracranial hemorrhage, myocardial infarction, vascular death, stroke, dual antiplatelet therapy, antiplatelet therapy, drug safety and efficacy comparison
- MeSH terms
- Clopidogrel, Ticagrelor, Adenosine, Aged, Double-Blind Method, Dyspnea, Electrocardiography, Female, Hemorrhage, Humans, Male, Myocardial Infarction, Platelet Aggregation Inhibitors, Ticlopidine, Stroke, Kaplan-Meier Estimate, Acute Coronary Syndrome, Purinergic P2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.